Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sat Dec 16 18:21:31 GMT 2023
by
admin
on
Sat Dec 16 18:21:31 GMT 2023
|
| Source Materials Class | ORGANISM |
| Source Materials Type | ALLOGENIC HUMAN |
| Source Materials State | KILLED |
| Source Materials Parent | |
| Part | EMBRYONIC KIDNEY CELL |
| Record UNII |
PRT7W2L4WZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PRT7W2L4WZ
Created by
admin on Sat Dec 16 18:21:31 GMT 2023 , Edited by admin on Sat Dec 16 18:21:31 GMT 2023
|
PRIMARY | |||
|
12385
Created by
admin on Sat Dec 16 18:21:31 GMT 2023 , Edited by admin on Sat Dec 16 18:21:31 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
ASP7517 is expected to have effects against WT1-expressing tumors by inducing both
natural killer (NK) cell activity (innate immunity) and WT1-specific T cell activity (adaptive immunity)
IN-VITRO, IN-VIVO
|
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| CHEMICAL | ALPHA-GALACTOSYLCERAMIDE | WX671898JF | |||
| CHEMICAL | DOXYCYCLINE | N12000U13O | |||
| LENTIVIRAL TRANSFECTION | TRANSFECTION | BIOLOGICAL | Torulimogene lonferencel rtTA vector | SHM2BH7BDK | |
| INACTIVATION | PHOTOCHEMICAL | UNSPECIFIED SUBSTANCE | 26cec4c2 | ||
| LENTIVIRAL TRANSFECTION | TRANSFECTION | Torulimogene lonferencel WT1 vector | 2LL2YKR3G2 | ||
| LENTIVIRAL TRANSFECTION | TRANSFECTION | Torulimogene lonferencel 1d vector | FN2DB7C5CS |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| VECTOR EXPRESSED PROTEIN | WILMS TUMOR PROTEIN ISOFORM D | WYG87YV56T |